Galectin‐3 promotes <scp>CXCR</scp>2 to augment the stem‐like property of renal cell carcinoma

Huang, Chang; Tang, Shanshan; Lee, Hsuan-Shu; Wang, Chien Chih Chang; Sun, Guang; Sun, Kien-Wen

doi:10.1111/jcmm.13860

Cited by 19 publications

(21 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further, it was not clear why serum levels of CXCL7 were higher in the male than in the female group. We speculate that CXCL7 may be influenced or regulated by key factors such as MEIS1 (Myeloid Ecotropic Viral Integration Site 1) and Galectin-3 (31, 32). If possible, we plan to measure these relevant indices in the future.…”

Section: Discussionmentioning

confidence: 99%

Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer

Zhang

Tian

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

Identification of effective biomarkers is crucial for monitoring the treatment and remission of colorectal cancer (CRC) and improving survival. It is particularly important to diagnose CRC before the tumor metastasizes (stage I–II disease) where possible, to provide the greatest opportunity for patient recovery. Here, we evaluated the clinical value of serum chemokine (C-X-C) ligand 7 (CXCL7) concentration as a biomarker for CRC diagnosis. An enzyme-linked immunosorbent assay was used to measure CXCL7 concentration in 560 serum samples from patients with CRC and controls. Logistic regression and receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic efficacy and build mathematical diagnostic models. The concentration of CXCL7 in the CRC group was significantly higher than that in the control group (P < 0.001), with an area under the ROC curve (AUC) value of 0.862 [95% confidence interval (CI): 0.831–0.890]. Further, the AUC of a regression model including the markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 125 (CA125), along with CXCL7, was 0.933 (95% CI: 0.909–0.952). For stage I–II tumors, CXCL7 had the highest AUC (0.823, 95% CI: 0.783–0.858) among the four individual biomarkers. The AUC value for combination model analysis of samples from patients with stage I–II tumors was 0.904 (95% CI: 0.872–0.930), with a sensitivity of 82.76% and a specificity of 87.14%, and an optimal cut-off value of 2.66. AUC values for application of the regression model in subgroup analysis were 0.947 (0.917–0.968) and 0.919 (0.874–0.951) for males and females, respectively. These results suggest that CXCL7 has potential as a serum diagnostic biomarker for detection of CRC. Importantly, the combination of CXCL7, CEA, CA125, and CA19-9 may facilitate diagnosis of CRC with relatively high sensitivity and specificity.Clinical Trial Registration Number: LS2017001.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer

Zhang

Tian

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Although little is known about Gal-3 function in CSCs, Gal-3 expression has been reported in CSCs from ovarian, gastrointestinal, kidney, and lung tumors (22)(23)(24)(25)(26). CSCs have been implicated in the development and progression of primary lesions and metastases (27).…”

Section: Introductionmentioning

confidence: 99%

Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis

et al. 2020

View full text Add to dashboard Cite

Galectin-3 (Gal-3) is an extracellular matrix glycan-binding protein with several immunosuppressive and pro-tumor functions. The role of Galectin-3 in cancer stem-like cells (CSCs) is poorly investigated. Here, we show that prostate CSCs also colonizing prostate-draining lymph nodes of transgenic adenocarcinoma of the mouse prostate (TRAMP) mice overexpress Gal-3. Gal-3 contributes to prostate CSC-mediated immune suppression because either Gal-3 silencing in CSCs, or co-culture of CSCs and T cells in the presence of the Gal-3 inhibitor N-Acetyl-D-lactosamine rescued T cell proliferation. N-Acetyl-D-lactosamine also rescued the proliferation of T cells in prostate-draining lymph nodes of TRAMP mice affected by prostate intraepithelial neoplasia. Additionally, Gal-3 impacted prostate CSC tumorigenic and metastatic potential in vivo, as Gal-3 silencing in prostate CSCs reduced both primary tumor growth and secondary invasion. Gal-3 was also found expressed in more differentiated prostate cancer cells, but with different intracellular distribution as compared to CSCs, which suggests different functions of Gal-3 in the two cell populations. In fact, the prevalent nuclear and cytoplasmic distribution of Gal-3 in prostate CSCs made them less susceptible to apoptosis, when compared to more differentiated prostate cancer cells, in which Gal-3 was predominantly intra-cytoplasmic. Finally, we found Gal-3 expressed in human and mouse prostate intraepithelial neoplasia lesions and in metastatic lymph nodes. All together, these findings identify Gal-3 as a key molecule and a potential therapeutic target already in the early phases of prostate cancer progression and metastasis.

show abstract

“…Tumor cells with low expression of α-N-acetylgalactosaminide α-2,6-sialyltransferase 2 show enhanced binding of soluble Gal3, which promotes homotypic and heterotypic aggregation, facilitating emboli formation and metastasis (Murugaesu et al, 2014). Moreover, in renal cell carcinoma, Gal3 augments stemness and progression via up-regulation of the CXCR2 chemokine (Huang et al, 2018), whereas in lung cancer, Gal3 contributes to metastatic niche formation through binding to Thomsen-Friedenreich antigen on metastatic tumor cells (Reticker-Flynn and Bhatia, 2015).…”

Section: Activating Invasion and Metastasismentioning

confidence: 99%

Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression

Girotti

Salatino

Dalotto-Moreno

et al. 2019

Journal of Experimental Medicine

133

123

View full text Add to dashboard Cite

Hanahan and Weinberg have proposed 10 organizing principles that enable growth and metastatic dissemination of cancer cells. These distinctive and complementary capabilities, defined as the “hallmarks of cancer,” include the ability of tumor cells and their microenvironment to sustain proliferative signaling, evade growth suppressors, resist cell death, promote replicative immortality, induce angiogenesis, support invasion and metastasis, reprogram energy metabolism, induce genomic instability and inflammation, and trigger evasion of immune responses. These common features are hierarchically regulated through different mechanisms, including those involving glycosylation-dependent programs that influence the biological and clinical impact of each hallmark. Galectins, an evolutionarily conserved family of glycan-binding proteins, have broad influence in tumor progression by rewiring intracellular and extracellular circuits either in cancer or stromal cells, including immune cells, endothelial cells, and fibroblasts. In this review, we dissect the role of galectins in shaping cellular circuitries governing each hallmark of tumors, illustrating relevant examples and highlighting novel opportunities for treating human cancer.

show abstract

Galectin‐3 promotes CXCR2 to augment the stem‐like property of renal cell carcinoma

Cited by 19 publications

References 41 publications

Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer

Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer

Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis

Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression

Contact Info

Product

Resources

About